Schaeffer's Top Stock Picks for '25

SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout

SAGE stock has more than doubled in value over the past month

Dec 7, 2017 at 10:18 AM
facebook X logo linkedin


Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) shot to a record high of $169.58 out of the gate, and were last seen trading up 68.6% at $154.77. For the second time in a month, the biotech reported successful trial results for one of its depression drugs, this time announcing that 64% of patients using its major depressive disorder (MDD) treatment entered remission 15 days in. On Nov. 9, SAGE Therapeutics gave positive data for its postpartum depression drug, Brexanolone.

In reaction, Canaccord Genuity raised its price target on the stock to $191 from $140, calling "the long-rage prospects for SAGE positive." More bullish brokerage notes are sure to come down the pike, considering the average 12-month price target for the security stands at $126.36 -- a nearly 19% discount to current trading levels.

SAGE options traders, meanwhile, are bracing for a quick retreat. Amid a surge in early options volume -- 3,010 contracts have traded, six times what's typically seen at this point in the day -- traders appear to be buying to open the December 145 put. If this is the case, they expect the shares to fall back below $145 by expiration at next Friday's close.

Given the stock's brow-raising 143.2% one-month gain, though, it's possible shareholders are initiating options hedges to guard paper profits against any downside risk. Whatever the motive, it's not cheap to buy premium on short-term SAGE options at the moment. The stock's Schaeffer's Volatility Index (SVI) of 239% ranks in the 100th annual percentile, meaning heightened volatility expectations are being priced in.

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?

 

 

(function(doc, script) { var js, fjs = doc.getElementsByTagName(script)[0], frag = doc.createDocumentFragment(), add = function(url, id) { if (doc.getElementById(id)) {return;} js = doc.createElement(script); js.src = url; id && (js.id = id); frag.appendChild( js ); }; // Google+ button //add('https://apis.google.com/js/platform.js', async="defer"); // Facebook SDK add('//connect.facebook.net/en_US/all.js#xfbml=1&appId=772755279557744', 'facebook-jssdk'); // Twitter SDK //add('//platform.twitter.com/widgets.js', charset='utf-8'); fjs.parentNode.insertBefore(frag, fjs); }(document, 'script'));